A novel thromboxane A2 receptor D304N variant which abrogates ligand binding in a patient with a bleeding diathesis

AD Mumford, Ban Dawood, ME Daly, SL Murden, Michael Williams, MB Protty, JC Spalton, Mark Wheatley, SJ Mundell, Steve Watson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We investigated the cause of mild mucocutaneous bleeding in a 14 year old male (P1). Platelet aggregation and ATP secretion induced by arachidonic acid and the thromboxane A(2) receptor (TxA(2)R) agonist U46619 were reduced in P1 compared to controls, whereas the responses to other platelet agonists were retained. P1 was heterozygous for a transversion within the TBXA2R gene predictive of a D304N substitution in the TxA(2)R. In CHO-K1 cells expressing the variant D304N TxA(2)R, U46619 did not increase cytosolic free Ca(2+) concentration indicating loss of receptor function. The TxA(2)R antagonist [(3)H]-SQ29548 showed an approximate 50% decrease in binding to platelets from P1 but absent binding to CHO-K1 cells expressing variant D304N TxA(2)R. This is the second naturally occurring TxA(2)R variant to be associated with platelet dysfunction and the first in which loss of receptor function is associated with reduced ligand binding. D304 lies within a conserved NPXXY motif in transmembrane domain 7 of the TxA(2)R that is a key structural element in family A G protein-coupled receptors. Our demonstration that the D304N substitution causes clinically significant platelet dysfunction by reducing ligand binding establishes the importance of the NPXXY motif for TxA(2)R function in vivo.
Original languageEnglish
JournalBlood
DOIs
Publication statusPublished - 14 Oct 2009

Fingerprint

Dive into the research topics of 'A novel thromboxane A2 receptor D304N variant which abrogates ligand binding in a patient with a bleeding diathesis'. Together they form a unique fingerprint.

Cite this